Navigation Links
International study suggests improved treatment alternative for lymphoid leukemia
Date:2/11/2013

CINCINNATI Discovering what they call the "Achilles' heel" for lymphoid leukemia, an international research team has tested a possible alternative treatment that eradicated the disease in mouse models.

Reporting their results Feb. 11 in the journal Cancer Cell, the scientists said the targeted molecular therapy described in their study could have direct implications for current treatment of Acute Lymphoid Leukemia (ALL) in people.

Led by researchers at Cincinnati Children's Hospital Medical Center and the Institut de recherches cliniques de Montreal (ICRM), the study found that leukemic cells depend on a protein called Gfi1 for survival. Removing the protein in mouse models of the disease weakened and killed the leukemia cells. Researchers said this should make the leukemia more susceptible to chemo and radiation therapies the current frontline treatments for ALL.

"Chemo and radiation therapies are very non-specific and can be toxic to patients. Our findings suggest that combining the inhibition of Gfi1 with these treatments may allow the use of lower cytotoxic doses and directly benefit patients," said H. Leighton Grimes, PhD, co-senior investigator on the study and researcher in the divisions of Cellular and Molecular Immunology and Experimental Hematology at Cincinnati Children's.

Also collaborating was co-senior investigator, Tarik Mry, PhD, president and scientific director of the ICRM in Montreal.

The researchers said the need for better treatment options is evident. Beside the potential toxicity of current therapeutic options, many ALL patients relapse after initial remission of their disease.

A cancer that affects blood cells and the immune system, ALL is the most common type of leukemia in children from infancy up to age 19, according to the Leukemia and Lymphoma Society of America. ALL occurs most often in the first decade of life but increases in frequency again in older individuals. According to the National Cancer Institute, the overall survival rate for all ages of people with ALL is 66.4 percent and 90.8 percent for children under the age of 5 years.

During the onset of a disease like ALL, cancer signals among cells activate a protein called p53, which is often referred to as the "guardian of the genome." A repressor of tumor growth, p53 normally initiates a DNA repair program that is supposed to induce programmed cell death to stop or slow down tumor progression.

In the case of ALL, the researchers said the disease relies on the Gfi1 protein to get around p53's tumor repressing capabilities by essentially overriding p53. Gfi1 has an important role in the normal development of lymphoid cells. But analyses of ALL mouse models and primary human tumors showed that Gfi1 is overexpressed in the disease state.

When the researchers removed Gfi1 in established mouse lymphoid tumors, the leukemia regressed through p53-induced cell death. Next, to see if removal of Gfi1 would be effective in modeled human ALL, the research team inserted T-cell leukemia cells from human patients into mice. Inhibiting Gfi1 in this instance stopped the progression of human leukemia in the animals without any harmful effects.

The scientists are continuing their research to see if results of the current study will be translatable to human patients.


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Related medicine news :

1. 15th International Celiac Disease Symposium will unveil new research, dispel gluten-free myths
2. OXIS International Reports 2012 Year End Revenue Exceeds $340,000.
3. Cigars International Rolls up a Bundle of Workforce Optimization Features to Help Bring Their Vision of the Customer Experience to Life
4. International network to study the causes behind IBS
5. GeneCell International and its Subsidiary Celulas Madre Latin America Opens State-of-the-Art Clinical Laboratory, BIOCEMA, to Serve Thousands of Families in Venezuela
6. At least 1 in 5 were infected in flu pandemic, international study suggests
7. Xocai's New Xe Product Provides An Incentive For Marketing Xocolate International Corporation (MXI Corp) Distributors To Launch Their Business To A Whole New Level
8. TekLink International Inc. Announces 30% Increase in Revenue for 2012
9. A Delicious, And Healthy New Seasonal Hot Chocolate Beverage, Xocai's Sipping Xocolate, Has Been Released By Marketing Xocolate International Corporation (MXI Corp)
10. Natural Source International Introduces New 'Recipe For Health'
11. AkAsha International Launches Children's Book Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... The Business Architecture Guild ... Reston, VA on March 21-22, 2017. This premier event features business practitioners and ... a cross-section of industries such as financial services, insurance, healthcare, manufacturing, transportation, retail, ...
(Date:12/7/2016)... Mateo, CA (PRWEB) , ... December 07, 2016 , ... ... San Francisco Peninsula region, is proud to announce new city-specific pages as part of ... services for the elderly, they often look, first, for local agencies serving their city. ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
(Date:12/6/2016)... Los Angeles, CA (PRWEB) , ... December 06, ... ... to suffer from erectile dysfunction because of a higher risk of serious health ... article on Star2.com. Dr. Peiman Soleymani of Beverly Hills Periodontics & ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... According to ... surprising habits, such as consuming too many mints or not drinking enough water, which ... Group and California Dental Care notes that good oral hygiene not only helps reduce ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 2016 Boehringer Ingelheim today announced that ... unresectable malignant pleural mesothelioma (MPM) met its primary ... at the 17 th IASLC World Conference ... , showed nintedanib plus pemetrexed/cisplatin demonstrated a meaningful ... a significantly improved PFS (9.4 vs 5.7 months). ...
(Date:12/7/2016)... 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), the ... company overview at the BMO Capital Markets Prescriptions for Success Healthcare ... . A live webcast of the presentation will ... website.  The replay will be available within 48 hours and will ... ...
(Date:12/7/2016)... -- Lannett Company, Inc. (NYSE: LCI ) today announced that ... for Success Healthcare Conference on December 14, 2016 at 9:20 a.m. ... City . In addition, the company will host ... th Annual Boston Healthcare Conference taking place on December 13, ... ...
Breaking Medicine Technology: